These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23259957)

  • 1. Incorporation of monodisperse oligoethyleneglycol amino acids into anticonvulsant analogues of galanin and neuropeptide y provides peripherally acting analgesics.
    Zhang L; Klein BD; Metcalf CS; Smith MD; McDougle DR; Lee HK; White HS; Bulaj G
    Mol Pharm; 2013 Feb; 10(2):574-85. PubMed ID: 23259957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of lipidization-cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities.
    Green BR; White KL; McDougle DR; Zhang L; Klein B; Scholl EA; Pruess TH; White HS; Bulaj G
    J Pept Sci; 2010 Sep; 16(9):486-95. PubMed ID: 20645434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities.
    Bulaj G; Green BR; Lee HK; Robertson CR; White K; Zhang L; Sochanska M; Flynn SP; Scholl EA; Pruess TH; Smith MD; White HS
    J Med Chem; 2008 Dec; 51(24):8038-47. PubMed ID: 19053761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling.
    Green BR; Klein BD; Lee HK; Smith MD; Steve White H; Bulaj G
    Bioorg Med Chem; 2013 Jan; 21(1):303-10. PubMed ID: 23176753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generating orally active galanin analogues with analgesic activities.
    Robertson CR; Pruess TH; Grussendorf E; White HS; Bulaj G
    ChemMedChem; 2012 May; 7(5):903-9. PubMed ID: 22374865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.
    Metcalf CS; Klein BD; McDougle DR; Zhang L; Smith MD; Bulaj G; White HS
    J Pharmacol Exp Ther; 2015 Jan; 352(1):185-93. PubMed ID: 25347995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticonvulsant neuropeptides as drug leads for neurological diseases.
    Robertson CR; Flynn SP; White HS; Bulaj G
    Nat Prod Rep; 2011 Apr; 28(4):741-62. PubMed ID: 21340067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galanin-neuropeptide Y (NPY) interactions in central cardiovascular control: involvement of the NPY Y receptor subtype.
    Díaz-Cabiale Z; Parrado C; Rivera A; de la Calle A; Agnati L; Fuxe K; Narváez JA
    Eur J Neurosci; 2006 Jul; 24(2):499-508. PubMed ID: 16903855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery.
    Robertson CR; Scholl EA; Pruess TH; Green BR; White HS; Bulaj G
    J Med Chem; 2010 Feb; 53(4):1871-5. PubMed ID: 20121116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Galanin N-terminal fragment (1-15) interacts with neuropeptide Y in central cardiovascular control: Involvement of the NPY Y2 receptor subtype.
    Díaz-Cabiale Z; Parrado C; Narváez M; Millón C; Puigcerver A; Fuxe K; Narváez JA
    Regul Pept; 2010 Aug; 163(1-3):130-6. PubMed ID: 20451563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models.
    White HS; Scholl EA; Klein BD; Flynn SP; Pruess TH; Green BR; Zhang L; Bulaj G
    Neurotherapeutics; 2009 Apr; 6(2):372-80. PubMed ID: 19332332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic neuropeptide W suppresses seizures in the brain revealed by rational repositioning and peptide engineering.
    Green BR; Smith M; White KL; White HS; Bulaj G
    ACS Chem Neurosci; 2011 Jan; 2(1):51-6. PubMed ID: 22826747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues.
    Zhang L; Robertson CR; Green BR; Pruess TH; White HS; Bulaj G
    J Med Chem; 2009 Mar; 52(5):1310-6. PubMed ID: 19199479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice.
    Karlsson RM; Holmes A; Heilig M; Crawley JN
    Pharmacol Biochem Behav; 2005 Mar; 80(3):427-36. PubMed ID: 15740785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel anticonvulsant neuropeptide and galanin analogue, NAX-5055, does not alter energy and amino acid metabolism in cultured brain cells.
    Aldana BI; Waagepetersen HS; Schousboe A; White HS; Bulaj G; Walls AB
    J Neurosci Res; 2017 Nov; 95(11):2286-2296. PubMed ID: 28397993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2.
    Metcalf CS; Smith MD; Klein BD; McDougle DR; Zhang L; Bulaj G
    Neurochem Res; 2017 Jul; 42(7):1983-1994. PubMed ID: 28382595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anticonvulsant action of the galanin receptor agonist NAX-5055 involves modulation of both excitatory- and inhibitory neurotransmission.
    Walls AB; Flynn SP; West PJ; Müller MS; Bak LK; Bulaj G; Schousboe A; White HS
    Epilepsy Res; 2016 Mar; 121():55-63. PubMed ID: 26894875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anatomical relations between neuropeptide Y, galanin, and gonadotropin-releasing hormone in the brain of chondrostean, the Siberian sturgeon Acipenser baeri.
    Amiya N; Amano M; Tabuchi A; Oka Y
    Neurosci Lett; 2011 Oct; 503(2):87-92. PubMed ID: 21871949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of glucose and insulin release following acute and repeated treatment with the synthetic galanin analog NAX-5055.
    Flynn SP; White HS
    Neuropeptides; 2015 Apr; 50():35-42. PubMed ID: 25690510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ketogenic diet does not alter brain expression of orexigenic neuropeptides.
    Tabb K; Szot P; White SS; Liles LC; Weinshenker D
    Epilepsy Res; 2004 Nov; 62(1):35-9. PubMed ID: 15519130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.